Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | Rel |
| Gene Name: | REL |
| Protein Full Name: | REL protein |
| Alias: | c-Rel; C-Rel protein; I-Rel; REL; RELC-Rel proto-oncogene protein; v-rel reticuloendotheliosis viral oncogene; v-rel reticuloendotheliosis viral oncogene homolog (avian) |
| Mass (Da): | 65225 |
| Number AA: | 587 |
| UniProt ID: | Q04864 |
| Locus ID: | 5966 |
| COSMIC ID: | REL |
| Gene location on chromosome: | 2p13-p12 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20689 |
| Percent of cancer specimens with mutations: | 0.41 |
| Found in amplified chromosomal regions in human cancers: | Lymphomas |
| Transduced into viral genome: | Reticuloendotheliosis virus - Turkey |
| Normal role description: | REL is a proto-oncogenic transcription factor that is part of the Rel/NFKB family and contains a highly conserved N-terminal region named the 'Rel domain', responsible for binding to DNA, dimerization, nuclear localization, and IκB binding. It is involved in the regulation of cell-cell interactions, intercellular communication, cell recruitment/transmigration, amplification, apoptosis, and in the initiation/acceleration of tumorigenesis. Amplification of the gene is frequently seen in lymphomas. |
| Commentary on involvement of protein in cancer: | 1/185 breast cancer-, and 1 pharyngeal/4 total UAT samples were also mutated (non-sense) |